Abstract
After acute coronary events, patients remain at high risk for recurrent cardiovascular events and mortality. Despite the compelling scientific and clinical trial evidence that statin therapy reduces mortality in patients after acute coronary events, this life-saving therapy continues to be underutilized. It is now recognized that the setting in which statin therapy is initiated has a major impact on patient adherence. In-hospital initiation of statin therapy has been demonstrated to result in a markedly increased treatment rate, improved long-term patient compliance, more patients reaching low-density lipoprotein levels less than 100 mg/dL, and improved long-term clinical outcomes. As long-term risk reduction is seen with statin therapy irrespective of baseline low-density lipoprotein cholesterol, virtually all acute coronary event patients are candidates for statin treatment. In-hospital initiation of statin therapy may also reduce early clinical events in acute coronary syndrome patients, but further research is required before this is fully established. The adoption of in-hospital initiation of statin therapy as the standard of care for patients hospitalized with acute coronary events will dramatically improve treatment rates and thus substantially reduce the risk of future coronary events and prolong life in the large number of patients hospitalized each year.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
American Heart Association: 2003 Heart and Stroke Statistical Update. Dallas: American Heart Association; 2002.
Rosamond WD, Chambless LE, Folsom AR, et al.: Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998, 339:861–867.
Rossouw JE, Lewis B, Rifkind BM: The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990, 323:1112–1119.
Smith SC, Blair SN, Bono RO, et al.: AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Circulation 2001, 104:1577–1579.
The 4S Investigators: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383–1389.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349–1357.
Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7–22.
Grundy SM, Cleeman JI, Rifkind BM, et al.: Cholesterol lowering in the elderly population. Arch Intern Med 1999, 159:1670–1678.
Mosca L, Grundy SM, Judelson D, et al.: Guide to preventive cardiology for women. AHA/ACC Scientific Statement Consensus panel statement. Circulation 1999, 99:2480–2484.
Grundy SM, Benjamin IJ, Burke GL, et al.: Diabetes and cardiovascular disease. a statement for healthcare professionals from the American Heart Association. Circulation 1999, 100:1134–1146.
Pearson TA, McBride PE, Miller NH, et al.: 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol 1996, 27:957–1047.
Adult Treatment Panel II: Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 1993, 269:3015–3023.
Adult Treatment Panel III: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001, 285:2486–2497.
Hunninghake DB, Stein EA, Dujovne CA, et al.: The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med 1993, 328:1213–1219.
Ramsay LE, Yeo WW, Jackson PR: Dietary reduction of serum cholesterol concentration: time to think again. BMJ 1991, 303:953–957.
Debusk RF, Miller NH, Superko HR, et al.: A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med 1994, 120:721–729.
Challenges and opportunities in quantifying the quality of care for acute myocardial infarction: summary from the Acute Myocardial Infarction Working Group of the American Heart Association/American College of Cardiology First Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke.Circulation 2003, 107:1681–1691.
Lee TH, Cleeman JI, Grundy SM, et al.: Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease. JAMA 2000, 283:94–98.
Fonarow GC, French WJ, Parsons LS, et al., for the National Registry of Myocardial Infarction 3 Participants: Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 2001, 103:38–44.
Aronow HD, Topol EJ, Roe MT, et al.: Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001, 357:1063–1068.
Stenestrand U, Wallentin L, for the Swedish Register of Cardiac Intensive Care (RIKS-HIA): Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001, 285:430–436.
Newby LK, Kristinsson A, Bhapkar MV, et al.: Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002, 287:3087–3095.
Sueta CA, Chowdhury M, Boccuzzi SJ, et al.: Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999, 83:1303–1307.
Jacobson TA, Griffiths GG, Varas C, et al.: Impact of evidence-based “clinical judgment” on the number of American adults requiring lipid-lowering drug therapy based on updated NHANES III data. Arch Intern Med 2000, 160:1361–1369.
Pearson TA, Laurora I, Chu H, et al.: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000, 160:459–467.
Pearson TA, Peters TD, Feury D, et al.: The American College of Cardiology Evaluation of Preventative Therapeutics (ACCEPT) study: attainment of goals for comprehensive risk reduction in patients with coronary disease in the US. J Am Coll Cardiol 1998, 31:186A.
EUROASPIRE II Study Group: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Program. Eur Heart J 2001, 22:554–572.
Jackevicius CA, Mamdani M, Tu JV: Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002, 288:462–467.
Muhlestein JB, Horne BD, Bair TL, et al.: Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001, 87:257–261.
Pearson TA, McBride PE, Miller NH, et al.: 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 8. Organization of preventive cardiology service. J Am Coll Cardiol 1996, 27:1039–1047.
Fonarow GC, Gawlinski A: Rationale and design of the cardiac hospitalization atherosclerosis management program at the University of California Los Angeles. Am J Cardiol 2000, 85:10A-17A.
Gore JM, Goldberg RJ, Matsumoto AS, et al.: Validity of serum total cholesterol level obtained within 24 hours of acute myocardial infarction. Am J Cardiol 1984, 54:722–725.
Rosenson RS: Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 1993, 22:933–940.
Fonarow GC, Stevenson LW, Walden JA, et al.: Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol 1997, 30:725–732.
Taylor CB, Houston-Miller N, Killen JD, et al.: Smoking cessation after acute myocardial infarction: effects of a nurse-managed intervention. Ann Intern Med 1990, 113:118–123.
Marciniak TA, Ellerbeck EF, Radford MJ, et al.: Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. JAMA 1998, 279:1351–1357.
Fonarow GC, Gawlinski A, Moughrabi S, et al.: Improved treatment of cardiovascular disease by implementation of a cardiac hospitalization atherosclerosis management program: CHAMP. Am J Cardiol 2001, 87:819–822.
Birtcher KK, Bowden C, Ballantyne CM, et al.: Strategies for implementing lipid-lowering therapy: pharmacy-based approach. Am J Cardiol 2000, 85:30A-35A.
Cannon CP, McCabe CH, Bentley J, et al.: Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: observations from OPUS-TIMI-16. J Am Coll Cardiol 2001, 37:334A.
McCarthy M: US heart-guidelines program makes a promising start. Lancet 2001, 358:1618.
Mehta RH, Montoye CK, Gollogly M, et al.: Improving quality of care for acute myocardial infarction. The guidelines applied into practice (GAP) initiative. JAMA 2002, 287:1269–1276.
Schwartz GG, Olsson AG, Ezekowitz MD, et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711–1718.
Liem AH, van Boven AJ, Veeger NJ, et al.: Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J 2002, 23:1931–1917.
Thompson PL, Amerena J, Campbell TJ, et al., on behalf of the PACT Investigators: Presented at the World Congress of Cardiology. Sydney, May 2002.
Heeschen C, Hamm CW, Laufs U, et al.: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002, 105:1446–1452.
Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998, 279:1643–1650.
Kwak B, Mulhaupt F, Myit S, et al.: Statins as a newly recognized type of immunomodulator. Nat Med 2000, 6:1399–1402.
Blazing MA, De Lemos JA, Dyke CK, et al.: The A-to-Z trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of an early aggressive simvastatin therapy. Am Heart J 2001, 142:211–217.
Cannon CP, McCabe CH, Belder R, et al.: Pravastatin or atorvastatin evaluation and infection therapy (PROVE IT). TIMI 22 Trial: rationale and design. Am J Cardiol 2002, 89:860–861.
Fonarow GC, Ballantyne CM: In-hospital initiation of lipid lowering therapy for patients with coronary heart disease: the time is now. Circulation 2001, 103:2768–2770.
Braunwald E, Antman EM, Beasley JW, et al.: ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2002, 106:1893–1900.
Fonarow GC: Treating to goal: new strategies for initiating and optimizing lipid-lowering therapies in patients with atherosclerosis. Vasc Med 2002, 7:187–194.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fonarow, G.C. In-hospital initiation of statin therapy in patients with acute coronary events. Curr Atheroscler Rep 5, 394–402 (2003). https://doi.org/10.1007/s11883-003-0011-4
Issue Date:
DOI: https://doi.org/10.1007/s11883-003-0011-4